TipRanks
Cassava: An Attractive Value Proposition
Let’s rewind back to the start of last year, to a period when Cassava Sciences (SAVA) shares began their ascent to a higher place; investors had evidently cottoned on to the potential of the company’s prospective Alzheimer’s disease (AD) treatment simufilam. In clinical studies, the drug demonstrated an ability to improve patients’ cognitive behaviour after 6 months, 9 months and then 12 months of therapy, a feat no other AD drug had achieved before. However, the company’s reputation has been ta